References
- 1. Cuzick J, Thorat M, Andriole G, et al. Prevention and Early Detection of Prostate Cancer. Lancet Oncol. 2014 Oct; 15(11): e484– e492. doi: 10.1016/S1470-2045(14)70211-610.1016/S1470-2045(14)70211-6
- 2. Khullar K, Parikh R. The role of radiotherapy in metastatic prostate cancer. Am J Clin Exp Urol. 2019; 7(2): 92–97.
- 3. Byrne T. A Review of Prostate Motion With Considerations for the Treatment of Prostate Cancer. Med Dosim. Fall 2005; 30(3):155-61. doi: 10.1016/j.meddos.2005.03.005.10.1016/j.meddos.2005.03.00516112467
- 4. Gawlik – Jakubczak T, Matuszewski M. Fiducial markers in the treatmentof prostate cancer: technique and short term observation. Oncology in Clinical Practice. 2015; Vol. 11, No. 6, 295–299.
- 5. Piotrowski T. Wybrane zagadnienia dotyczące planowania leczenia w radioterapii. Wielkopolskie Centrum Onkologii.
- 6. Chen Z, Yang Z, Wang J, Hu W. Dosimetric impact of different bladder and rectum filling during prostate cancer. Radiation Oncology. 2016, Vol 11, Article number: 103.
- 7. Yartsev S, Bauman G. Target margins in radiotherapy of prostate cancer. Br J Radiol. November 2016; 89(1067): 20160312. doi: 10.1259/bjr.20160312.10.1259/bjr.20160312512483827377353
- 8. Bodusz D, Głowacki G, Miszczyk L. Ocena śródfrakcyjnej ruchomości gruczołu krokowego w trakcie radioterapii chorych na raka stercza. Nowotwory. Journal of Oncology. 2011; 61(5):439.
- 9. Antico M, et al. Real-time adaptive planning method for radiotherapy treatment delivery for prostate cancer patients, based on a library of plans accounting for possible anatomy configuration changes. PLoS One. 2019; 14(2): e0213002. doi: 10.1371/journal.pone.0213002.10.1371/journal.pone.0213002639496030818345
- 10. Oborska D. Obrazowanie w radioterapii - kryteria jakości obrazów MV vs kV, planarne vs wolumetryczne. II Konferencja z zakresu detekcji promieniowania jonizującego oraz kontroli jakości w rentgenodiagnostyce, radioterapii i medycynie nuklearnej, Klimówka, Poland, Maj 2015.
- 11. Merriel S, Funston G, Hamilton W. Prostate Cancer in Primary Care. Adv Ther. 2018; 35(9): 1285–1294. doi: 10.1007/s12325-018-0766-1.10.1007/s12325-018-0766-1613314030097885
- 12. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr; 10(2): 63–89. doi: 10.14740/wjon1191.10.14740/wjon1191649700931068988
- 13. Chen F, Zhao X. Prostate Cancer: Current Treatment and Prevention Strategies. Iran Red Crescent Med J. 2013 Apr; 15(4): 279–284. doi: 10.5812/ircmj.6499.10.5812/ircmj.6499378589824082997
- 14. Koukourakis G, Kelekis N, Armonis V, Kouloulias V. Brachytherapy for Prostate Cancer: A Systematic Review. Adv Urol. 2009; 2009: 327945. doi: 10.1155/2009/327945.10.1155/2009/327945273574819730753
- 15. Lam Cham Kee D, Peiffert D, J-M Hannoun-Lévi. Brachytherapy Boost for Prostate Cancer: A National Survey From Groupe curiethérapie - Société française De radiothérapie Oncologique. Cancer Radiother. 2019 Dec;23(8):847-852. doi: 10.1016/j.canrad.2019.06.003.10.1016/j.canrad.2019.06.00331375324
- 16. Posiewnik M, Piotrowski T. A review of cone-beam CT applications for adaptive radiotherapy of prostate cancer. European Journal of Medical Physics. Vol 59, p 13-21, March 2019.10.1016/j.ejmp.2019.02.01430928061
- 17. Yaver M, Foo A, Larsen T, et. al. Consistency of Organ Geometries During Prostate Radiotherapy With Two Different Bladder and Bowel Regimens. J Med Imaging Radiat Sci. 2015 Dec;46(4):380-387. doi: 10.1016/j.jmir.2015.09.001.10.1016/j.jmir.2015.09.001
- 18. Ren W, Sun Ch, Lu N, et. al, Dosimetric Comparison of Intensity-Modulated Radiotherapy and Volumetric-Modulated Arc Radiotherapy in Patients With Prostate Cancer: A Meta-Analysis. J Appl Clin Med Phys. 2016 Nov 8;17(6):254-262. doi: 10.1120/jacmp.v17i6.6464.10.1120/jacmp.v17i6.6464
- 19. McNair H, Hansen V, Parker Ch, et. al. A Comparison of the Use of Bony Anatomy and Internal Markers for Offline Verification and an Evaluation of the Potential Benefit of Online and Offline Verification Protocols for Prostate Radiotherapy. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):41-50. doi: 10.1016/j.ijrobp.2007.09.002.10.1016/j.ijrobp.2007.09.002
- 20. O’Neill A, Jain S, Hounsell A, et. al. Fiducial marker guided prostate radiotherapy: a review. Br J Radiol. December 2016; 89(1068): 20160296. doi: 10.1259/bjr.20160296.10.1259/bjr.20160296
- 21. Pérez-Romasanta L, Lozano-Martín E, Velasco-Jiménez J, et. al. CTV to PTV Margins for Prostate Irradiation. Three-dimensional Quantitative Assessment of Interfraction Uncertainties Using Portal Imaging and Serial CT Scans. Clin Transl Oncol. 2009 Sep;11(9):615-21.doi: 10.1007/s12094-009-0413-z.10.1007/s12094-009-0413-z
- 22. Kukołowicz P, Kukołowicz H, Tyburska I. Dependence of the Safe Rectum Dose on the CTV-PTV Margin Size and Treatment Technique. Rep Pract Oncol Radiother. May-Jun 2015;20(3):198-203. doi: 10.1016/j.rpor.2014.12.004.10.1016/j.rpor.2014.12.004
- 23. Ziółkowski S, Biedka M, Żmuda E, Ziółkowska E. Trudności w przeprowadzeniu radioterapii u chorych z otyłością. Inżynier i Fizyk Medyczny. 2014, Vol. 3, p 111-116.
- 24. Lin L, Hertan L, Rengan R, et. al. Effect of Body Mass Index on Magnitude of Setup Errors in Patients Treated With Adjuvant Radiotherapy for Endometrial Cancer With Daily Image Guidance. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):670-5.doi: 10.1016/j.ijrobp.2011.07.026.10.1016/j.ijrobp.2011.07.026
- 25. Bentzen S, Constine L, Deasy J, et. al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues. Int J Radiat Oncol Biol Phys. 2010 Mar 1; 76(3 Suppl): S3–S9. doi: 10.1016/j.ijrobp.2009.09.040.10.1016/j.ijrobp.2009.09.040
- 26. NCNN (National Comrehensive Cancer Network) Guidelines Version 2.2017.
- 27. NCNN (National Comrehensive Cancer Network) Guidelines Version 1.2020.
- 28. Piziorska M, Kukołowicz P, Zawadzka A, et. al. Adaptive off-line protocol for prostate external radiotherapy with cone beam computer tomography. Strahlentherapie und Onkologie. 2012. Vol. 188, p 1003–1009.
- 29. McKenzie A, Herk M, Mijnheer B. Margins for Geometric Uncertainty Around Organs at Risk in Radiotherapy. Radiother Oncol. 2002 Mar;62(3):299-307. doi: 10.1016/s0167-8140(02)00015-4.10.1016/S0167-8140(02)00015-4